Have you been diagnosed with non-clear cell RCC? Clinical trials are an excellent way for patients to access new treatments for rare subtypes. This chart lists all active and enrolling clinical trials for non-clear cell RCC.
Click on the NCI Trial ID to learn more about each non-clear cell RCC trial including eligibility criteria and information about enrollment. Listing a study is not an endorsement of any clinical trial.
To learn more about the different subtypes of RCC, click here.
If you have information about non-clear cell clinical trials or would like to suggest an addition or change, contact Info@kccure.org.
|NCI Trial ID||Histology||Treatment||Phase||Locations|
|NCT03075423 SUNIFORECAST||Non-clear Cell RCC||Ipilimumab + nivolumab vs. sunitinib||II||Germany|
|NCT03685448||Non-clear Cell RCC||Cabozantinib for patients post-immunotherapy or who are ineligible for immunotherapy||II||Australia|
|NCT03635892||Non-Clear Cell RCC||[Nivolumab + cabozantinib] (immunotherapy + targeted therapy)||II||NJ, NY|
|NCT03117309||Non-Clear Cell & Clear Cell RCC||Nivolumab and [nivolumab + ipilimumab] (combination immunotherapy)||II||DC, IL, MA, NJ, NY, OH, PA, TX|
|NCT03149822||Non-Clear Cell & Clear Cell RCC||[Pembrolizumab + cabozantinib] (immunotherapy and targeted therapy)||I/II||CO|
|NCT03055013 PROSPER RCC||Non-Clear Cell & Clear Cell RCC (Neoadjuvant Therapy - Non-metastatic)||Nivolumab prior to and after nephrectomy (neoadjuvant immunotherapy)||III||38 states in U.S.|
|NCT02721732||Renal Medullary Carcinoma, Non-Clear Cell and Clear Cell||Pembrolizumab (immunotherapy)||II||Houston, TX|
|NCT02019693||Papillary RCC||Capmatinib (INC280) (targeted therapy MET inhibitor)||II||Bethesda, MD (NIH)|
|NCT03866382||Papillary RCC, Chromophobe RCC, Sarcomatoid RCC and Renal Medullary Carcinoma ||[Nivolumab + ipilimumab + cabozantinib] (combination immunotherapy and targeted therapy)||II||ID, MT, NE, OR, WY|
|NCT03595124||Translocation XP11.2||[Nivolumab + axitinib] or axitinib or nivolumab (immunotherapy and/or targeted therapy)||II||25 states in U.S.|
|NCT03274258||Renal Medullary Carcinoma (RMC)||[Nivolumab + ipilumumab] (combination immunotherapy)||II||Houston, TX|
|NCT02496208||Renal Medullary Carcinoma, Sarcomatoid RCC, Clear Cell RCC, and Other Rare Kidney Cancer Histology||[Nivolumab + cabozantinib] or [nivolumab + ipilimumab + cabozantinib] (immunotherapy + targeted therapy)||I||CA, MD, NJ, OH|
|NCT03587662||Renal Medullary Carcinoma and other tumors with loss of SMARCB1; including adult-onset rhabdoid tumors||Ixazomib, Gemcitabine and Doxorubicin (chemotherapy + targeted therapy)||II||Houston, TX|
|NCT03541902||Variant histology RCC (vhRCC) Including Papillary RCC, Chromophobe RCC, Xp11.2 Translocation, Undifferentiated and Unclassified RCC||Cabozantinib or sunitinib (targeted therapy)||II||Houston, TX|
|NCT02465060 MATCH||Genetic Based Kidney Cancer (Therapy directed by genetic testing)||22 different targeted therapy agents for EGFR, HER2, MET, ALK, ROS1, BRAF, PIK3CA, mTOR, TSC1, TSC2, PTEN, NF1, GNAQ, GNA11, SMO, PTCH1, NF2, cKIT, FGFR, DDR2 S768R, I638F, L239R, AKT, NRAS, CCND, CDK4, CDK6, MLH, NTRK, BRCA gene mutations||II||50 states in the U.S.|
|NCT04068831||FH/SDH positive tumors||Avelumab (PD-L1 inhibitor) + Talazoparib (PARP inhibitor)||II||New York, NY|
|NCT03097328||All types of RCC||TAK-228||II||CA, CO, IL, MA, MI, MN|
|NCT04152018||Papillary RCC||PF-06940434||I||AZ, CA, MO, TX, WA|
|NCT04338269||Papillary and Unclassified||Cabozantinib compared to Cabo + atezolizumab||III||26 states in the U.S., open at locations in Europe, South American, Australia and Asia|